Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib

Haematologica. 2008 Feb;93(2):317-8. doi: 10.3324/haematol.11680.

Abstract

Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values.

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Benzamides
  • Creatine Kinase / metabolism*
  • Female
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
  • Lipid Metabolism / drug effects*
  • Male
  • Metabolic Diseases / chemically induced*
  • Metabolic Diseases / metabolism
  • Middle Aged
  • Phosphates / metabolism*
  • Piperazines / administration & dosage
  • Piperazines / adverse effects*
  • Pyrimidines / administration & dosage
  • Pyrimidines / adverse effects*
  • Retrospective Studies

Substances

  • Antineoplastic Agents
  • Benzamides
  • Phosphates
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Creatine Kinase